SOUTH SAN FRANCISCO, Calif., March 24, 2025–Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today provided an update on the company’s development pipeline and reported financial results for the fiscal year ended December 31, 2024.Read More
Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results
